| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.02 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.074 | 0.02 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |